<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271478</url>
  </required_header>
  <id_info>
    <org_study_id>FIS/IMSS/PROT/G09/739</org_study_id>
    <secondary_id>Registry CLIS</secondary_id>
    <nct_id>NCT01271478</nct_id>
  </id_info>
  <brief_title>Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients</brief_title>
  <official_title>Effect of Telmisartan and Captopril on Systemic Inflammation of Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the dual use of telmisartan and captopril vs the
      individual use of such drugs and placebo on the systemic inflammation of patients on
      hemodialysis (HD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once included, patients will be randomly allocated (by a computer-generated randomization
      list) to one of the following groups: group 1 will receive Captopril, group 2 Telmisartan,
      group 3 Captopril plus Telmisartan, and group 4 Placebo. Drugs will be provided as tablets
      during a period of 3 months. All patients will have 3 HD sessions per week, with the same
      kind of single-use dialysis membrane and dialysate Monthly visits will be scheduled for
      clinical and biochemical evaluations. A blood sample will be taken at baseline and every
      month for measurement of complete blood count, urea, creatinine, glucose, albumin, lipids,
      and electrolytes (measured by usual methods). In serum samples at 0, 1 and 3 months, tumor
      necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) concentrations will be measured by
      ELISA using high sensitivity kits. Additionally, in the same serum samples, C-reactive
      protein (CRP) concentrations will be measured by nephelometry using high sensitivity kits.
      All laboratory measurements, including inflammation markers, will be performed in the Central
      Laboratory (Hospital de Especialidades, Centro Médico Nacional de Occidente), by the same
      personnel blinded to patient's details.

      Treatment compliance will be recorded by counting tablets left in the container at the end of
      each monthly visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of TNF-a, IL-6 and CRP</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Inflammation</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Telmisartan plus Captopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Captopril plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets of placebo orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>captopril plus placebo</intervention_name>
    <description>This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
    <arm_group_label>Captopril plus Placebo</arm_group_label>
    <other_name>Capotena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan plus placebo</intervention_name>
    <description>Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day</description>
    <arm_group_label>Telmisartan plus Placebo</arm_group_label>
    <other_name>micardis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan plus Captopril</intervention_name>
    <description>Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)</description>
    <arm_group_label>Telmisartan plus Captopril</arm_group_label>
    <other_name>Capotena</other_name>
    <other_name>Micardis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this group will receive 2 tablets of placebo (starch) twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  ≥2 months on hemodialysis

          -  Arteriovenous fistula as vascular access

          -  Endorsement of informed consent

        Exclusion Criteria:

          -  Inflammatory cause of ESRD

          -  Liver disease, cancer, AIDS

          -  Any infectious disease 2 months before the study

          -  Failed kidney graft

          -  Hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin receptor
             blockers

          -  Arterial hypotension

          -  Pregnancy

          -  Treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids,
             immunosuppressives, statins, ACE inhibitors or ARB 3 months previous to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso M. M Cueto-Manzano, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad de Investigación Médica en Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Especialidades, CMNO, IMSS</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ordaz-Medina SM, González-Plascencia J, Martín del Campo F, Rojas-Campos E, Montañez-Fernández JL, Espinoza-Gómez F, Cueto-Manzano AM. Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial. ASAIO J. 2010 Jan-Feb;56(1):37-41. doi: 10.1097/MAT.0b013e3181c1d830.</citation>
    <PMID>20051840</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Alfonso Martín Cueto Manzano</investigator_full_name>
    <investigator_title>Head, Medical Research Unit of Renal Diseases</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>telmisartan</keyword>
  <keyword>captopril</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

